|
CO-ADMINISTRATION HAS RESULTED IN CONVULSIONS
|
INCREASED RISK OF RESPIRATORY DEPRESSION
|
INCREASED RISK OF MYOCARDIAL DEPRESSION
|
INCREASED RISK OF MYOCARDIAL DEPRESSION, SEIZURES
|
PHENYTOIN ENHANCES THE DRUG METABOLISM HENCE DECREASED SERUM LEVELS HAVE BEEN OBSERVED
|
DIURETICS CAUSED HYPOKALEMIA MAY ANTAGONISE THE EFFECTS OF LIGNOCAIN
|
DIURETICS CAUSED HYPOKALEMIA MAY ANTAGONISE THE EFFECTS OF LIGNOCAIN
|
DIURETICS CAUSED HYPOKALEMIA MAY ANTAGONISE THE EFFECTS OF LIGNOCAIN
|
DIURETICS CAUSED HYPOKALEMIA MAY ANTAGONISE THE EFFECTS OF LIGNOCAIN
|
DIURETICS CAUSED HYPOKALEMIA MAY ANTAGONISE THE EFFECTS OF LIGNOCAIN
|
DIURETICS CAUSED HYPOKALEMIA MAY ANTAGONISE THE EFFECTS OF LIGNOCAIN
|
DIURETICS CAUSED HYPOKALEMIA MAY ANTAGONISE THE EFFECTS OF LIGNOCAIN
|
DIURETICS CAUSED HYPOKALEMIA MAY ANTAGONISE THE EFFECTS OF LIGNOCAIN
|
DIURETICS CAUSED HYPOKALEMIA MAY ANTAGONISE THE EFFECTS OF LIGNOCAIN
|
DIURETICS CAUSED HYPOKALEMIA MAY ANTAGONISE THE EFFECTS OF LIGNOCAIN
|
DIURETICS CAUSED HYPOKALEMIA MAY ANTAGONISE THE EFFECTS OF LIGNOCAIN
|
DIURETICS CAUSED HYPOKALEMIA MAY ANTAGONISE THE EFFECTS OF LIGNOCAIN
|
DIURETICS CAUSED HYPOKALEMIA MAY ANTAGONISE THE EFFECTS OF LIGNOCAIN
|
DIURETICS CAUSED HYPOKALEMIA MAY ANTAGONISE THE EFFECTS OF LIGNOCAIN
|
DIURETICS CAUSED HYPOKALEMIA MAY ANTAGONISE THE EFFECTS OF LIGNOCAIN
|
DIURETICS CAUSED HYPOKALEMIA MAY ANTAGONISE THE EFFECTS OF LIGNOCAIN
|
DIURETICS CAUSED HYPOKALEMIA MAY ANTAGONISE THE EFFECTS OF LIGNOCAIN
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
CALCIUM CHANNEL BLOCKERS POTENTIATE THE DEPRESSION OF CARDIAC CONTRACTILITY, CONDUCTIVITY, AND AUTOMATICITY AS WELL AS VASCULAR DILATION ASSOCIATED WITH ANESTHETICS
|
INCREASED SEDATIVE EFFECT
|
OPIOID ANALGESICS RESPIRATORY DEPRESSANT EFFECT IS ENHANCED
|
OPIOID ANALGESICS RESPIRATORY DEPRESSANT EFFECT IS ENHANCED
|
OPIOID ANALGESICS RESPIRATORY DEPRESSANT EFFECT IS ENHANCED
|
OPIOID ANALGESICS RESPIRATORY DEPRESSANT EFFECT IS ENHANCED
|
OPIOID ANALGESICS RESPIRATORY DEPRESSANT EFFECT IS ENHANCED
|
OPIOID ANALGESICS RESPIRATORY DEPRESSANT EFFECT IS ENHANCED
|
OPIOID ANALGESICS RESPIRATORY DEPRESSANT EFFECT IS ENHANCED
|
OPIOID ANALGESICS RESPIRATORY DEPRESSANT EFFECT IS ENHANCED
|
OPIOID ANALGESICS RESPIRATORY DEPRESSANT EFFECT IS ENHANCED
|
OPIOID ANALGESICS RESPIRATORY DEPRESSANT EFFECT IS ENHANCED
|
OPIOID ANALGESICS RESPIRATORY DEPRESSANT EFFECT IS ENHANCED
|
OPIOID ANALGESICS RESPIRATORY DEPRESSANT EFFECT IS ENHANCED
|
OPIOID ANALGESICS RESPIRATORY DEPRESSANT EFFECT IS ENHANCED
|
OPIOID ANALGESICS RESPIRATORY DEPRESSANT EFFECT IS ENHANCED
|
OPIOID ANALGESICS RESPIRATORY DEPRESSANT EFFECT IS ENHANCED
|
OPIOID ANALGESICS RESPIRATORY DEPRESSANT EFFECT IS ENHANCED
|
OPIOID ANALGESICS RESPIRATORY DEPRESSANT EFFECT IS ENHANCED
|
OPIOID ANALGESICS RESPIRATORY DEPRESSANT EFFECT IS ENHANCED
|
RANITIDINE MAY REDUCE CLEARANCE OF THE DRUG AND HENCE INCREASE BIOAVAILABILITY
|
CIMETIDINE DECREASES RENAL CLEARANCE OF THE DRUG LEADING TO INCREASED PLASMA LEVELS
|
CO-ADMINISTRATION HAS RESULTED IN DELIRIUM
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
NEUROMUSCULAR BLOCKING EFFECT IS ENHANCED
|
NEUROMUSCULAR BLOCKING EFFECT IS ENHANCED
|
NEUROMUSCULAR BLOCKING EFFECT IS ENHANCED
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
LIGNOCAIN TOXICITY MAY BE PRECIPITATED DUE TO CO-ADMINISTRATION
|
LOCAL ANAESTHETICS SYSTEMIC TOXICITY MAY BE POTENTIATED BY CONCURRENT USE
|
LOCAL ANAESTHETICS SYSTEMIC TOXICITY MAY BE POTENTIATED BY CONCURRENT USE
|
LOCAL ANAESTHETICS SYSTEMIC TOXICITY MAY BE POTENTIATED BY CONCURRENT USE
|
LOCAL ANAESTHETICS SYSTEMIC TOXICITY MAY BE POTENTIATED BY CONCURRENT USE
|
LOCAL ANAESTHETICS SYSTEMIC TOXICITY MAY BE POTENTIATED BY CONCURRENT USE
|
LOCAL ANAESTHETICS SYSTEMIC TOXICITY MAY BE POTENTIATED BY CONCURRENT USE
|
LOCAL ANAESTHETICS SYSTEMIC TOXICITY MAY BE POTENTIATED BY CONCURRENT USE
|
BETABLOCKERS ESPECIALLY PROPRANOLOL MAY REDUCE RENAL CLEARANCE OF THE DRUG LEADING TO INCREASED BIOAVAILABILITY
|
BETABLOCKERS ESPECIALLY PROPRANOLOL MAY REDUCE RENAL CLEARANCE OF THE DRUG LEADING TO INCREASED BIOAVAILABILITY
|
BETABLOCKERS ESPECIALLY PROPRANOLOL MAY REDUCE RENAL CLEARANCE OF THE DRUG LEADING TO INCREASED BIOAVAILABILITY
|
BETABLOCKERS ESPECIALLY PROPRANOLOL MAY REDUCE RENAL CLEARANCE OF THE DRUG LEADING TO INCREASED BIOAVAILABILITY
|
BETABLOCKERS ESPECIALLY PROPRANOLOL MAY REDUCE RENAL CLEARANCE OF THE DRUG LEADING TO INCREASED BIOAVAILABILITY
|
BETABLOCKERS ESPECIALLY PROPRANOLOL MAY REDUCE RENAL CLEARANCE OF THE DRUG LEADING TO INCREASED BIOAVAILABILITY
|
BETABLOCKERS ESPECIALLY PROPRANOLOL MAY REDUCE RENAL CLEARANCE OF THE DRUG LEADING TO INCREASED BIOAVAILABILITY
|
BETABLOCKERS ESPECIALLY PROPRANOLOL MAY REDUCE RENAL CLEARANCE OF THE DRUG LEADING TO INCREASED BIOAVAILABILITY
|
BETABLOCKERS ESPECIALLY PROPRANOLOL MAY REDUCE RENAL CLEARANCE OF THE DRUG LEADING TO INCREASED BIOAVAILABILITY
|